ArticleJournal of bacteriology1997
The TolA protein interacts with colicin E1 differently than with other group A colicins.
Article in Journal of bacteriology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Origin and Evolution of Bacterial Periplasmic Force Transducers.Molecular biology and evolution · 2025Article
- Article
- Tunable force transduction through theProceedings of the National Academy of Sciences of the United States of America · 2023Article
- The multifarious roles of Tol-Pal in Gram-negative bacteria.FEMS microbiology reviews · 2020Review
- Similarities and Differences between Colicin and Filamentous Phage Uptake by Bacterial Cells.EcoSal Plus · 2019Review
- Rapid production and characterization of antimicrobial colicins usingSynthetic biology (Oxford, England) · 2018Article
- The Colicin E1 TolC Box: Identification of a Domain Required for Colicin E1 Cytotoxicity and TolC Binding.Journal of bacteriology · 2017Article
- The Colicin E1 TolC-Binding Conformer: Pillar or Pore Function of TolC in Colicin Import?Biochemistry · 2016Article
- Repetitive genomic insertion of gene-sized dsDNAs by targeting the promoter region of a counter-selectable marker.Scientific reports · 2015Article
- Antibacterial toxin colicin N and phage protein G3p compete with TolB for a binding site on TolA.Microbiology (Reading, England) · 2015Article
- Rational optimization of tolC as a powerful dual selectable marker for genome engineering.Nucleic acids research · 2014Article
- Structural evidence that colicin A protein binds to a novel binding site of TolA protein in Escherichia coli periplasm.The Journal of biological chemistry · 2012Article
- Variation of intragenic tandem repeat tract of tolA modulates Escherichia coli stress tolerance.PloS one · 2012Article
- Interaction of the colicin K bactericidal toxin with components of its import machinery in the periplasm of Escherichia coli.Journal of bacteriology · 2010Article
- Toxicogenomic response of Pseudomonas aeruginosa to ortho-phenylphenol.BMC genomics · 2008Article
- Initial steps of colicin E1 import across the outer membrane of Escherichia coli.Journal of bacteriology · 2007Article
- Colicin biology.Microbiology and molecular biology reviews : MMBR · 2007Review
- Tol-dependent macromolecule import through the Escherichia coli cell envelope requires the presence of an exposed TolA binding motif.Journal of bacteriology · 2005Article
- Competing ligands stabilize alternate conformations of the energy coupling motif of a TonB-dependent outer membrane transporter.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Structure of the periplasmic domain of Pseudomonas aeruginosa TolA: evidence for an evolutionary relationship with the TonB transporter protein.The EMBO journal · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The 421-residue protein TolA is required for the translocation of group A colicins (colicins E1, E2, E3, A, K, and N) across the cell envelope of Escherichia coli. Mutations in TolA can render cells tolerant to these colicins and cause hypersensitivity to detergents and certain antibiotics, as well as a tendency to leak periplasmic proteins. TolA contains a long alpha-helical domain which connects a membrane anchor to the C-terminal domain, which is required for colicin sensitivity. The functional role of the alpha-helical domain was tested by deletion of residues 56 to 169 (TolA delta1), 166 to 287 (TolA delta2), or 54 to 287 (TolA delta3) of the alpha-helical domain of TolA, which removed the N-terminal half, the C-terminal half, or nearly the entire alpha-helical domain of TolA, respectively. TolA and TolA deletion mutants were expressed from a plasmid in an E. coli strain producing no chromosomally encoded TolA. Cellular sensitivity to the detergent deoxycholate was increased for each deletion mutant, implying that more than half of the TolA alpha-helical domain is necessary for cell envelope stability. Removal of either the N- or C-terminal half of the alpha-helical domain resulted in a slight (ca. 5-fold) decrease in cytotoxicity of the TolA-dependent colicins A, E1, E3, and N compared to cells producing wild-type TolA when these mutants were expressed alone or with TolQ, -R, and -B. In cells containing TolA delta3, the cytotoxicity of colicins A and E3 was decreased by a factor of >3,000, and K+ efflux induced by colicins A and N was not detectable. In contrast, for colicin E1 action on TolA delta3 cells, there was little decrease in the cytotoxic activity (<5-fold) or the rate of K+ efflux, which was similar to that from wild-type cells. It was concluded that the mechanism(s) by which cellular uptake of colicin E1 is mediated by the TolA protein differs from that for colicins A, E3, and N. Possible explanations for the distinct interaction and unique translocation mechanism of colicin E1 are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.